MAIA Biotechnology Inc. (AMEX: MAIA), the clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, completed enrollment for its phase 2 trial for THIO, its lead therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback